NCT05137496

Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome

A Single-center, Prospective, Non-comparative Clinical Trial of Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Beijing Friendship Hospital · Academic / Other
• Sex: All
• Age: 1 Year – 75 Years
• Healthy volunteers: Not accepted

Summary

The present study was a single-center, prospective, non-comparative in which macrophage activation syndrome patients were selected as the main subjects to evaluate the effect and safety of Ruxolitinib and methylprednisolone regimens as the first-line therapy .

Conditions

• Macrophage Activation Syndrome

Interventions

Type	Name	Description
DRUG	Ruxolitinib	0.3mg/kg/d, iv.gtt, for at least 2 weeks
DRUG	methylprednisolone	2mg/kg, d1-d5, gradually reduced, for at least 2 weeks

Timeline

• Start date: 2022-06-01
• Primary completion: 2023-06-01
• Completion: 2024-06-01
• First posted: 2021-11-30
• Last updated: 2022-03-17